68 results on '"Chuan Mo"'
Search Results
2. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus
3. # 1492 The incidence and predictors of hepatitis B surface antigen loss and hepatocellular carcinoma development after the cessation of lamivudine and entecavir treatment in chronic hepatitis B patients
4. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion
5. A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection
6. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma
7. Antiviral effect of entecavir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy
8. Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis
9. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection
10. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants
11. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
12. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients
13. Spontaneous clearance of hepatitis C virus in an interleukin 28B favorable genotype highly prevalent area
14. Community-based cross-sectional study: The association of lipids with hepatitis C seropositivity and diabetes mellitus
15. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy
16. Peripheral blood toll-like receptor mRNA expression is associated with rapid virological response in chronic hepatitis C genotype 1 patients who received pegylated interferon and ribavirin: 1044
17. Profiles and Clinical Significance of HBsAg Titer in Patients Receiving Peginterferon Alfa-2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses: 421
18. Virological response of entecavir monotherapy is associated with a lower probability of clinical disease progression in nucleos(t)ide analogue-experienced chronic epatitis B patients with cirrhosis: 404
19. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice
20. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy
21. Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients
22. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy
23. Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications
24. Diagnostic sensitivity of hepatocellular carcinoma imaging and its application to non-cirrhotic patients
25. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients
26. Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience
27. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease
28. Hepatic Steatosis with Hepatitis B Virus/Hepatitis C Virus Dual Infection
29. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening
30. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan
31. Favorable α-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation
32. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients
33. Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study
34. Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C
35. Pancreatic Head Cancer With Distant Duodenal Metastasis: A Case Report With Rare Endoscopic Presentations
36. Natural Course of Hepatic Focal Nodular Hyperplasia: A Long-Term Follow-up Study with Sonography
37. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups
38. Changing aetiology of liver dysfunction in the new generation of a hepatitis B and C-endemic area: cross-sectional studies on adolescents born in the first 10 years after universal hepatitis B vaccination
39. Overexpression of VEGF Is Associated With Positive p53 Immunostaining in Hepatocellular Carcinoma (HCC) and Adverse Outcome of HCC Patients
40. Steatosis correlates with hepatic expression of death receptors and activation of nuclear factor-κB in chronic hepatitis C
41. HBeAg-Negative Chronic Hepatitis B: Cost-Effectiveness of Peginterferon Alfa-2a Compared to Lamivudine in Taiwan
42. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy
43. Esophageal motility differences among aged patients with achalasia: A Taiwan report
44. Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors
45. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection
46. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study
47. Incidence of needle tract seeding and responses of soft tissue metastasis by hepatocellular carcinoma postradiotherapy
48. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response
49. Thrombocytopenia As A Surrogate for Cirrhosis and A Marker for the Identification of Patients at High-Risk for Hepatocellular Carcinoma
50. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.